Search PubMed⌕ Search

Biomedical subjects

Z Mechl

Publications and source records attributed to Z Mechl.

At least 37 records · Page 2Linked to original sources
PubMed1987

Comparative evaluation of two administration schedules of cis-dichlorodiammineplatinum (DDP) in ovarian and head and neck cancers: a CMEA chemotherapy group study.

The therapeutic effectivity of two administration schedules of DDP were compared. The dose was either 100 mg/m2 infused for 4 h or 20 mg/m2 infused for 1 h on 5 consecutive days. The combined objective remission rate of the two regimens were 37/53 (23% CR ++ 44% PR) for ovarian cancer and 8/35 (9% CR + 14% PR) for head and neck cancer. WHO Grade 1-2 myelo- and nephrotoxicity was observed in 26% and 20%, respectively, out of the 105 cases evaluable for toxicity in the two groups. Nausea and vomiting was moderate to severe. Neither the remission rate nor the toxicity of the two schedules were significantly different.

Adult↗
PubMed1986

Relation between dose, plasma concentration and toxicity in a phase I trial using high dose intermittent administration of an alkylating agent, diacetyldianhydrogalactitol (DADAG).

Diacetyldianhydrogalactitol (DADAG), a new alkylating sugar alcohol derivative, was administered as single, 30-min infusions in doses ranging from 390 to 1200 mg/m2. The dose-limiting toxicity was myelosuppression. The median times to WBC nadir and regeneration were 16 and 21 days, and to platelet nadir and recovery 20 and 27, respectively. Nausea and vomiting occurred frequently and were of moderate severity. For phase II studies 900 mg/m2 DADAG given every 4-6 weeks is recommended. The area under the plasma concentration time curve (AUC) for DADAG did not increase in proportion with dose escalation; it changed only from 235.5 +/- 70.7 to 262.4 +/- 71.5 micrograms h ml-1 between doses of 690 and 1050 mg/m2. No correlations between the dose administered and the nadir values for haemoglobin concentration, WBC and platelet counts, or the number of episodes of vomiting were demonstrable in this dose range. Such an association was revealed, however, when the above biological variables were related to the individual AUC for DADAG.

Adult↗
PubMed1986

[Current results with surgery and adjuvant chemotherapy in malignant melanoma].

The paper presents the results of three randomized trials for adjuvant chemo- and immunotherapy in malignant melanoma clinical stage II: 770 patients were treated by surgery, surgery + DTIC, surgery + BCG or surgery + DTIC + BCG, 248 patients were treated by surgery or surgery + poly-U-A; 40 patients were treated by surgery or surgery + vinblastine/bleomycine/cisplatinum. Neither the recidive free interval nor the survival could be enhanced by surgically adjuvant chemo- and immunotherapy in this group of patients.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1986

[Cisplatin (platidiame) in the treatment of patients with disseminated breast cancer].

In search of fresh indications for clinical application of cis-platinum, it was added to chemotherapy, the only treatment given to patients with disseminated breast cancer. The study group included 13 patients, with the data on 12 of them being subject to evaluation. The results showed a high antitumor effect of cis-platinum: objective remission was observed in 5 out of 12 cases (46.6%), with the complete 10 month-long remission included. All patients suffered from such untoward side-effects as sickness and vomiting. Moderate nephrotoxicity, which did not interfere with treatment, was registered in 3 cases. Since results confirmed the therapeutic effect of cis-platinum in breast cancer patients previously untreated with antitumor drugs further research into the problem should be recommended.

Breast Neoplasms↗
PubMed1986

Procarbazin in advanced malignant melanoma.

Experience in applying procarbazin in the treatment of advanced malignant melanoma are very limited. Actually it has never been adequately tested as monotherapy. We administered procarbazin to 28 patients in a dosis of 100 mg/m2 on days 1 to 10 at 4-week intervals. As a result we obtained 25% remissions which suggest that procarbazin deserves greater attention in the above indication.

Aged↗
PubMed1985

[4'-epidoxorubicin].

Explore the source record for details and available documents.

Antibiotics, Antineoplastic↗
PubMed1985

Medroxyprogesterone acetate versus tamoxifen in the therapy of advanced breast cancer.

A comparison of efficacies of medroxyprogesterone acetate (MPA) and the antiestrogen tamoxifen (TX) in the therapy for advanced breast cancer in patients who had already previously been intensely treated showed that, as to the objective remissions, the two drugs can be looked upon as equivalent. Nevertheless, with MPA a better analgetic and anabolic effect--a marked improvement in the performance status (Karnofsky index)--was achieved.

Breast Neoplasms↗
PubMed1984

[Acyclovir].

Explore the source record for details and available documents.

Acyclovir↗
PubMed1984

[Tiapride].

Explore the source record for details and available documents.

Analgesia↗
PubMed1984

[Experiences with cisplatin (Platidiam) chemotherapy in secondary resistant ovarian carcinomas].

Experiences with cis Platin therapy in cases of ovarian cancers after previous tumorchemotherapy are reported. 23 patients were treated with 100 mg cis Platin (DDP)/m2 (Lachema, CSSR, Brno) in intervals of four weeks following extensive hyperhydratation. We observed following therapeutic effects: CR 4 of 23 pat., PR 11 of 23 pat., NC 3 of 23 pat. and progression in 5 cases. The average remission-time was the best in cases with CR (8,3 month) and the worst in cases without any therapeutic effect (1 month). Side effects observed: severe vomiting was compulsory in all cases. Twice we observed neuro- and ototoxicity after the 5th respectively 6th cyclus. DDP is an effective but also toxic cytostatic drug for treatment of ovarian cancer in the 2nd or 3rd line. It should be used in cases of secondary resistant tumours.

Adolescent↗
PubMed1984

CAP (cyclophosphamide, adriamycin, cisplatinum) in the treatment of advanced breast cancer.

Fourteen patients with advanced carcinoma of the breast were treated with CAP combination therapy. An objective therapeutic response (partial remissions with a mean duration of 6.3 months) was achieved in 6 of 13 evaluated patients. This response was observed in soft tissue metastases. Nausea and vomiting were found to be the most frequent undesirable side effects in all patients and could not be avoided by administration of antiemetics. In 2 patients mild nephrotoxicity was found without any effects on further therapy. The results of this study were considered as promising; a definitive assessment of the CAP regimen is expected to come from a randomized study which started in the CMEA countries in 1983.

Antineoplastic Combined Chemotherapy Protocols↗